CTH Cotec Holdings Corp

Cynapsus Therapeutics Inc. (TSX VENTURE:CTH)(OTCQX:CYNAF), a specialty
pharmaceutical company, announced today that the Corporation's Board of
Directors granted stock options to acquire 2,256,000 common shares.


The stock options were granted to officers, directors, employees and a
consultant of the Corporation at an exercise price equal to $0.65 per share, and
expire 5 years from the date of grant. One third of the options granted will
vest immediately, one-third will vest in 6 months and one-third will vest in 12
months. Of the total, 884,000 stock options were granted to Anthony Giovinazzo
(President & CEO), 355,000 to Andrew Williams (COO/CFO), 350,000 to Albert Agro
(CMO), 102,000 to Rochelle Stenzler (Director), 64,000 to Ronald Hosking
(Director), 56,000 to Perry Molinoff (Director), 52,000 to Alan Ryley
(Director), 42,000 to Tomer Gold (Director) and 25,000 to Nan Hutchinson
(Director). The remaining 326,000 stock options were granted to employees and a
consultant of the Corporation.


Following the grant of these options, there are a total of 4,622,316 options
outstanding, representing 5.9% of the issued and outstanding common shares of
the Corporation.


The Corporation has a 10% rolling stock option plan. The TSX Venture Exchange
requires that all listed companies with a 10% rolling stock option plan, obtain
shareholder approval of the plan on an annual basis. The stock option plan was
most recently approved at the Annual and Special Meeting of the Shareholders
held on May 7, 2014. The stock option plan was established to provide an
incentive to the officers, directors, employees and consultants of the
Corporation to achieve the longer-term objectives of the Corporation, to give
suitable recognition to the ability and efforts of such persons who contribute
materially to the success of the Corporation, and to attract and retain such
persons in the employ of the Corporation.


About Cynapsus Therapeutics

Cynapsus is a specialty pharmaceutical company developing a convenient and easy
to use sublingual (oral) thin film strip for the acute rescue of "off" motor
symptoms of Parkinson's disease. Cynapsus' drug candidate, APL-130277, is an
easy-to-administer, fast-acting reformulation of apomorphine, which is the only
approved drug (in the United States, Europe, Japan and other countries) to
rescue patients from "off" episodes. Cynapsus is focused on maximizing the value
of APL-130277 by completing pivotal studies in advance of a New Drug Application
("NDA") expected to be submitted in 2016.


Over one million people in the U.S. and an estimated 4 to 6 million people
globally suffer from Parkinson's disease. Parkinson's disease is a chronic and
progressive neurodegenerative disease that impacts motor activity, and its
prevalence is increasing with the aging of the population. Based on a recent
study and the results of the Corporation's Global 500 Neurologists Survey, it is
estimated that between 25 percent and 50 percent of patients experience "off"
episodes in which they have impaired movement or speaking capabilities. Current
medications only control the disease's symptoms, and most drugs become less
effective over time as the disease progresses.


More information about Cynapsus (TSX VENTURE:CTH)(OTCQX:CYNAF) is available at
www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval
(SEDAR) at www.sedar.com. 


Forward Looking Statements

This announcement contains "forward-looking statements" within the meaning of
applicable securities laws. Generally, these forward-looking statements can be
identified by the use of forward-looking terminology such as "plans", "expects"
or "does not expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might" or "will be taken", "occur" or "be
achieved". Forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of Cynapsus to be materially different
from those expressed or implied by such forward-looking statements, including
but not limited to those risks and uncertainties relating to Cynapsus' business
disclosed under the heading "Risk Factors" in its March 26, 2014, Annual
Information Form and its other filings with the various Canadian securities
regulators which are available online at www.sedar.com. Although Cynapsus has
attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements, there may
be other factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove to be
accurate, as actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not place undue
reliance on forward-looking statements. Cynapsus does not undertake to update
any forward-looking statements, except in accordance with applicable securities
laws.


Neither the TSX Venture Exchange nor the OTCQX International has approved or
disapproved the contents of this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
ajg@cynapsus.ca


Cynapsus Therapeutics
Andrew Williams
COO & CFO
(416) 703-2449 x253
awilliams@cynapsus.ca
www.cynapsus.ca

Cotec (TSXV:CTH)
Historical Stock Chart
From Nov 2024 to Dec 2024

Cotec (TSXV:CTH)
Historical Stock Chart
From Dec 2023 to Dec 2024